CUBi001-A
General#
Cell Line |
|
| hPSCreg Name | CUBi001-A |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator |
Charité - Universitätsmedizin Berlin (CUB)
Contact:
Berlin Institute of Health (BIH) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA103992830 |
| Cellosaurus | CVCL_IT59 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research: allowed
Clinical: not allowed
Commercial: not allowed
|
Donor Information#
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | neonate |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46,XY
|
External Databases (Donor) |
|
| BioSamples | SAMEA103992831 |
Ethics#
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Provide contact information of the holder of the original Donor Information Sheet: | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Contact information / weblink | Dr. Peter Kühnen, Charité, Institut für Experimentelle Pädiatrische Endokronologie |
| If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? | Yes |
| Alternatives to consent | |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Details on restriction to research project | |
| Does consent permit unforeseen future research, without further consent? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Please describe how access is provided: | |
| Contact data, institution, or website: | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Commission of the Charite |
| Approval number | EA2/013/16 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Commission of the Charite |
| Approval number | EA2/013/16 |
| Please describe: | |
| Further constraints on use | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution |
hIPSC Derivation#
General |
|
| Source cell type |
fibroblast of dermis |
| Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
| Age of donor (at collection) | neonate |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-1 |
No |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
| Pluripotency Score | Novelty Score | Link to microarray data |
| 32.75 | 1.3 | http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5145 |
Morphology pictures
Transcriptome Characterisation
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Karyotyping method:
KaryoLite BoBs
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.